Edwards Lifesciences Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) increased by 7.0% to $1.19B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 68.2%, from $706.00M to $1.19B. This is a positive signal — higher values indicate stronger performance for this metric.
Higher amounts indicate greater near-term liquidity and the ability to reinvest at current market rates, which is beneficial in rising rate environments.
This metric measures the amortized cost of available-for-sale debt securities that are scheduled to mature within one ye...
Commonly used to assess the maturity profile and liquidity of bank balance sheets.
afs_debt_securities_amortized_cost_1y| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $212.10M | $203.60M | $305.90M | $258.20M | $379.30M | $366.50M | $450.90M | $435.80M | $422.80M | $295.90M | $721.10M | $706.00M | $745.40M | $1.11B | $1.19B |
| QoQ Change | — | -4.0% | +50.2% | -15.6% | +46.9% | -3.4% | +23.0% | -3.3% | -3.0% | -30.0% | +143.7% | -2.1% | +5.6% | +48.9% | +7.0% |
| YoY Change | — | — | — | +21.7% | +86.3% | +19.8% | +74.6% | +14.9% | +15.4% | -34.4% | +65.5% | +67.0% | +151.9% | +53.9% | +68.2% |